Christopher Raymond analyst PIPER SANDLER

Currently out of the existing stock ratings of Christopher Raymond, 375 are a BUY (80.3%), 87 are a HOLD (18.63%), 5 are a SELL (1.07%).

Christopher Raymond

Work Performance Price Targets & Ratings Chart

Analyst Christopher Raymond, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 49.66% that have a potential upside of 40.35% achieved within 249 days.

Christopher Raymond’s has documented 932 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 06-Nov-2024.

Wall Street Analyst Christopher Raymond

Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.

Average potential price target upside

ABBV AbbVie ACRS Aclaris Therapeutics AIMT Aimmune Therapeutics AKBA Akebia Ther ALVR Allovir  ALXN Alexion Pharmaceuticals AMAG AMAG Pharmaceuticals AMGN Amgen ARDX Ardelyx BIIB Biogen BMRN Biomarin Pharmaceutical COGT Cogent Biosciences DCPH Deciphera Pharmaceuticals LLC GRAY Graybug Vision INO Inovio Pharmaceuticals ONCR Oncorus  RARE Ultragenyx REGN Regeneron Pharmaceuticals APTX Aptinyx BPMC Blueprint Medicines Corp CELG Celgene INZY Inozyme Pharma  MGTX MeiraGTx Holdings PLC OTIC Otonomy RIGL Rigel Pharmaceuticals BOLD Audentes Therapeutics CBIO Catalyst Biosciences KNTE Kinnate Biopharma  PRVL Prevail Therapeutics SLDB Solid Biosciences LLC XLRN Acceleron Pharma BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd NUVL Nuvalent ALXO Alx Oncology Holdings  KPTI Karyopharm Therapeutics RMTI Rockwell Medical SPHS Sophiris Bio VECT VectivBio Holding AG VRTX Vertex Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$205

$39.27 (23.70%)

5 days ago
(15-Nov-2024)

2/3 (66.67%)

$39.27 (23.70%)

507

Buy

$200

$34.27 (20.68%)

$190

7 days ago
(13-Nov-2024)

12/13 (92.31%)

$28.57 (16.67%)

490

Buy

$215

$49.27 (29.73%)

$226

8 days ago
(12-Nov-2024)

8/10 (80%)

$39.86 (22.76%)

293

Buy

$224

$58.27 (35.16%)

$231

8 days ago
(12-Nov-2024)

12/15 (80%)

$48.86 (27.90%)

488

Buy

$221

$55.27 (33.35%)

$171

14 days ago
(06-Nov-2024)

22/23 (95.65%)

$18.37 (9.07%)

427

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Christopher Raymond is most bullish on?

Potential upside of $437.11 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Christopher Raymond is most reserved on?

Potential downside of -$6.59 has been obtained for KPTI (KARYOPHARM THERAPEUTICS)

What Year was the first public recommendation made by Christopher Raymond?

On 2006

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?